RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

 
Regulatory Focus™ > News Articles > 2020 > 3 > COVID-19 therapeutics tracker

COVID-19 therapeutics tracker

Posted 07 August 2020 | By Jeff Craven 

COVID-19 therapeutics tracker

As the COVID-19 pandemic continues, researchers and manufacturers are moving potential therapeutics into clinical trials at a dizzying pace. The search is on to find treatment candidates that lower mortality rates and lessen the severity of COVID-19.
 
To date, three therapeutics are approved to treat COVID-19: dexamethasone in the United Kingdom and Japan; Avigan (favilavir) in China, Italy and Russia; and Veklury (remdesivir) in Japan and Australia.
 
Potential therapies are being examined in several large international trials. The largest, SOLIDARITY, is led by the World Health Organization (WHO). More than 100 countries have joined SOLIDARITY to evaluate high-profile treatment candidates for COVID-19.

The pandemic has created unprecedented public/private partnerships. Operation Warp Speed (OWS) is a collaboration of several US federal government departments including Health and Human Services and its subagencies, Agriculture, Energy and Veterans Affairs and the private sector. Within OWS, the US National Institutes of Health (NIH) has partnered with more than 18 biopharmaceutical companies to accelerate development of drug and vaccine candidates for COVID-19 in a collaboration dubbed Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV).
 
The European Medicines Agency (EMA) is building procedures for accelerated drug and vaccine development, promising to offer rapid reviews for scientific advice, compliance, market authorization, extensions beyond indications and market authorizations, and compassionate use for COVID-19 related initiatives.
 
Once a leading candidate, hydroxychloroquine/chloroquine has been removed from the tracker due to evidence it can cause more harm than benefit in patients with COVID-19. It will be reinstated if evidence to the contrary arises.
  
This tracker will be updated weekly with the latest in developments for these treatment candidates. If you notice an issue with this data or wish to submit an update, please email Focus at news@raps.org.
 
Updated 7 August to include new entries for bucillamine and niclosamide as well as updated information on dexamethasone, Veklury, Kevzara, MK-4482 (formerly EIDD-2801), convalescent plasma, and LY-CoV555.


 

 

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe